Insulet Corporation — Q1 2012 Form 10-Q
Business and period: Unaudited results for the three months ended March 31, 2012, compared with the same period in 2011. Insulet develops, manufactures and markets the OmniPod insulin delivery system and, following its June 2011 acquisition of Neighborhood Diabetes, distributes additional diabetes supplies and pharmaceuticals.
Financial performance and position
| Metric | Q1 2012 | Q1 2011 / prior balance-sheet date |
|---|---|---|
| Revenue | $47.8 million | $28.3 million; up 69% |
| Gross profit and margin | $20.3 million; 42.5% | $13.5 million; 47.9% |
| Operating expenses | $31.2 million | $20.8 million |
| Operating loss | $10.9 million | $7.3 million |
| Net loss | $14.8 million; $0.31 per share | $9.8 million; $0.22 per share |
| Cash from operations | $(8.9) million | $(7.9) million |
| Cash and cash equivalents | $83.0 million | $94.0 million at December 31, 2011 |
| Current assets / current liabilities | $127.4 million / $32.6 million | $131.8 million / $28.0 million at December 31, 2011 |
| Convertible debt | $158.8 million principal; $110.8 million carrying value after discounts | $15.0 million of 5.375% notes due June 2013 and $143.8 million of 3.75% notes due June 2016 |
Operating cash use was partly offset by $8.8 million of non-cash adjustments. Investing used $1.7 million, mainly for manufacturing equipment; financing used $0.3 million. The accumulated deficit was $455.8 million. No off-balance-sheet financing arrangements were reported.
Changes versus Q1 2011
- Revenue rose $19.5 million, reflecting continued OmniPod adoption and Neighborhood Diabetes, which contributed $10.7 million of revenue from testing supplies and pharmaceuticals. The acquisition closed in June 2011, so the comparison includes an acquired business in 2012 but not in Q1 2011.
- Cost of revenue increased 86%, faster than revenue, and gross margin declined about 5.4 percentage points. Management attributed the increase to higher sales volume and the lower margins of Neighborhood Diabetes.
- Operating expenses rose 50%, with general and administrative expense up 81% and sales and marketing up 41%. Net loss increased by about 50%; higher interest expense also contributed.
- Cash declined $10.9 million during the quarter. Receivables and inventory increased by $3.9 million and $2.9 million, respectively; accounts payable and accruals provided a partial offset.
Outlook, commentary and risks
- Management expects 2012 revenue to increase, dependent on sales execution, adequate OmniPod production, successful introduction of the next-generation system, and international expansion. It expects research and development spending to decrease slightly from 2011, while general and administrative and sales and marketing expenses are expected to rise.
- Management expects near-term net losses as it invests in next-generation product approval and production capacity, sales-force expansion and the Neighborhood Diabetes business. It believes cash and expected product-sale proceeds will meet projected operating and debt-service needs for at least 12 months.
- Management says current manufacturing capacity is sufficient for expected 2012 demand. OmniPods are produced at a Flextronics-operated facility in China; the filing also identifies concentration of manufacturing capacity in China and inventory in Massachusetts as risks.
- Key risks include reimbursement and coverage, supplier availability and costs, reducing production costs, obtaining regulatory approval for the next-generation OmniPod, competition, and Neighborhood Diabetes retaining supplier pricing discounts and payor relationships.
- BD litigation alleges that the OmniPod infringes three patents; Insulet disputes the allegations and does not expect a material adverse impact, but acknowledges the outcome is uncertain. The company reports no material changes to the risk factors in its 2011 Form 10-K.
- The Ypsomed distribution agreement was amended in April 2012 to add countries and extend its term by one year. The filing gives no quantified revenue impact from this amendment.
Key facts for investors to verify
- Whether revenue growth and gross-margin recovery continue as OmniPod sales expand and the acquired distribution business contributes.
- Cash burn, working-capital needs and management’s liquidity estimate, including the timing and ability to service or refinance convertible-note obligations.
- Progress and timing of regulatory approval, manufacturing validation and launch of the next-generation OmniPod.
- Reimbursement coverage, payor and supplier retention, and Neighborhood Diabetes’ margins and integration performance.
- Developments in the BD patent litigation and any changes in manufacturing or inventory concentration risks.